Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II): Second European-Australasian Acute Stroke Study Investigators
Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II): Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;17:1245-1251
Intra-arterial prourokinase for acute ischemic stroke: The PROACT II study: A randomized controlled trial - Prolyse in Acute Cerebral Thromboembolism
Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial - Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003-2011
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587
Mechanical extraction of a basilar artery embolus with the use of flow reversal and a microbasket
Mayer TE, Hamann GF, Brueckmann H. Mechanical extraction of a basilar artery embolus with the use of flow reversal and a microbasket. N Engl J Med 2002;347:769-770
Risk factors for severe hemorrhagic transformation in ischemic strokepatients treated with recombinant tissue plasminogen activator: A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II)
Larrue V, von Kummer RR, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic strokepatients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001;32:438-441